GRAIL, Inc. GRAL
GRAL among the 162 companies we cover
Where it stands · the better end on the right. The band holds the middle half; the line is the median.
GRAL and 9 peers, year by year
The 9 Health care companies closest to GRAL in revenue over the last twelve months. Every number is from the 10-K and links to it in SEC's Inline XBRL viewer.
Choose the peers
| Company | Year | Revenue | Sales growth | Gross margin | Operating margin | Net margin | FCF margin | Return on equity | Debt / equity |
|---|---|---|---|---|---|---|---|---|---|
| GRAL GRAIL, Inc. | FY2025 | $147.2M | +17.2% | - | −382.0% | −277.5% | −203.8% | −15.8% | - |
| BEAM Beam Therapeutics Inc. | FY2025 | $139.7M | +120% | - | −274.6% | −57.2% | −257.7% | −6.5% | - |
| AGIO Agios Pharmaceuticals, Inc. | FY2025 | $54.0M | +48.0% | - | −873.9% | −764.0% | −698.3% | −34.6% | - |
| RVMD Revolution Medicines, Inc. | FY2025 | $0 | - | - | - | - | - | −69.3% | - |
| CYTK Cytokinetics Inc | FY2025 | $88.0M | +377% | - | −695.4% | −891.6% | −607.5% | n/m | n/m |
| KYMR Kymera Therapeutics, Inc. | FY2025 | $39.2M | −16.7% | - | −891.1% | −794.0% | −597.6% | −19.7% | - |
| LGND Ligand Pharmaceuticals Inc | FY2025 | $268.1M | +60.4% | - | 15.3% | 46.4% | 18.2% | 12.2% | - |
| RXRX Recursion Pharmaceuticals, Inc. | FY2025 | $74.7M | +26.9% | - | −867.9% | −863.4% | −506.5% | −57.0% | 0.02 |
| LMAT Lemaitre Vascular Inc | FY2025 | $249.6M | +13.5% | 71.5% | 27.2% | 23.1% | 29.8% | 14.7% | - |
| RYTM Rhythm Pharmaceuticals, Inc. | FY2025 | $189.8M | +45.8% | - | −101.2% | −103.6% | −61.5% | −141.3% | 0.78 |
Each company, year by year
Bars: revenue, each company on its own scale. Line: net margin, on one scale for all. FY2022 to FY2025 · 10-K XBRL
Who rewrote the most
Share of the words changed in Risk Factors and in MD&A, latest 10-K against the one before
Revenue, FY2022 to FY2025
Revenue as reported in the 10-K.
| Company | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| GRAL Dec | $55.5M | $93.1M | $125.6M | $147.2M |
| BEAM Dec | $60.9M | $377.7M | $63.5M | $139.7M |
| AGIO Dec | $14.2M | $26.8M | $36.5M | $54.0M |
| RVMD Dec | $35.4M | $11.6M | $0 | $0 |
| CYTK Dec | $94.6M | $7.5M | $18.5M | $88.0M |
| KYMR Dec | $46.8M | $78.6M | $47.1M | $39.2M |
| LGND Dec | $196.2M | $131.3M | $167.1M | $268.1M |
| RXRX Dec | $39.8M | $44.6M | $58.8M | $74.7M |
| LMAT Dec | $161.7M | $193.5M | $219.9M | $249.6M |
| RYTM Dec | $23.6M | $77.4M | $130.1M | $189.8M |
| Peer median | $46.8M | $77.4M | $58.8M | $88.0M |
Sales growth, FY2022 to FY2025
Revenue against the fiscal year before.
| Company | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| GRAL Dec | - | +67.6% | +34.9% | +17.2% |
| BEAM Dec | +17.5% | +520% | −83.2% | +120% |
| AGIO Dec | - | +88.4% | +36.1% | +48.0% |
| RVMD Dec | +20.4% | −67.3% | −100% | - |
| CYTK Dec | +34.3% | −92.0% | +145% | +377% |
| KYMR Dec | −35.7% | +67.8% | −40.1% | −16.7% |
| LGND Dec | −18.8% | −33.1% | +27.3% | +60.4% |
| RXRX Dec | +291% | +11.9% | +32.0% | +26.9% |
| LMAT Dec | +4.7% | +19.7% | +13.6% | +13.5% |
| RYTM Dec | +649% | +228% | +68.1% | +45.8% |
| Peer median | +18.9% | +19.7% | +27.3% | +46.9% |
Gross margin, FY2022 to FY2025
Gross profit / revenue.
Operating margin, FY2022 to FY2025
Operating income / revenue.
| Company | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| GRAL Dec | n/m | n/m | n/m | −382.0% |
| BEAM Dec | −555.6% | −46.7% | −654.3% | −274.6% |
| AGIO Dec | n/m | n/m | n/m | −873.9% |
| RVMD Dec | −730.0% | n/m | - | - |
| CYTK Dec | −342.8% | n/m | n/m | −695.4% |
| KYMR Dec | −344.4% | −210.6% | −555.8% | −891.1% |
| LGND Dec | 1.5% | 9.1% | −13.5% | 15.3% |
| RXRX Dec | −616.7% | −785.3% | −814.1% | −867.9% |
| LMAT Dec | 16.6% | 19.0% | 23.8% | 27.2% |
| RYTM Dec | −757.9% | −238.1% | −204.0% | −101.2% |
| Peer median | −450.0% | −128.7% | −379.9% | −485.0% |
Net margin, FY2022 to FY2025
Net income / revenue.
| Company | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| GRAL Dec | n/m | n/m | n/m | −277.5% |
| BEAM Dec | −474.5% | −35.1% | −593.1% | −57.2% |
| AGIO Dec | n/m | n/m | n/m | −764.0% |
| RVMD Dec | −703.0% | n/m | - | - |
| CYTK Dec | −411.2% | n/m | n/m | −891.6% |
| KYMR Dec | −330.6% | −187.0% | −475.6% | −794.0% |
| LGND Dec | −17.0% | 39.7% | −2.4% | 46.4% |
| RXRX Dec | −601.0% | −736.0% | −788.0% | −863.4% |
| LMAT Dec | 12.8% | 15.6% | 20.0% | 23.1% |
| RYTM Dec | −766.2% | −238.5% | −200.3% | −103.6% |
| Peer median | −442.9% | −111.0% | −337.9% | −433.8% |
Free cash flow, FY2022 to FY2025
Cash from operations minus capital spending.
| Company | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| GRAL Dec | −$584.2M | −$608.7M | −$582.4M | −$299.9M |
| BEAM Dec | −$26.4M | −$182.9M | −$356.2M | −$360.0M |
| AGIO Dec | −$314.4M | −$297.1M | −$391.5M | −$377.3M |
| RVMD Dec | −$235.2M | −$358.3M | −$567.7M | −$913.7M |
| CYTK Dec | −$310.9M | −$415.7M | −$399.8M | −$534.8M |
| KYMR Dec | −$155.9M | −$137.3M | −$207.3M | −$234.3M |
| LGND Dec | $119.9M | $46.1M | $95.2M | $48.9M |
| RXRX Dec | −$120.6M | −$299.7M | −$372.9M | −$378.3M |
| LMAT Dec | $22.1M | $29.5M | $37.2M | $74.5M |
| RYTM Dec | −$173.7M | −$136.2M | −$113.9M | −$116.6M |
| Peer median | −$155.9M | −$182.9M | −$356.2M | −$360.0M |
FCF margin, FY2022 to FY2025
Free cash flow / revenue.
| Company | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| GRAL Dec | n/m | −653.8% | −463.7% | −203.8% |
| BEAM Dec | −43.4% | −48.4% | −560.8% | −257.7% |
| AGIO Dec | n/m | n/m | n/m | −698.3% |
| RVMD Dec | −664.8% | n/m | - | - |
| CYTK Dec | −328.6% | n/m | n/m | −607.5% |
| KYMR Dec | −333.0% | −174.7% | −440.5% | −597.6% |
| LGND Dec | 61.1% | 35.1% | 57.0% | 18.2% |
| RXRX Dec | −302.6% | −672.4% | −633.7% | −506.5% |
| LMAT Dec | 13.7% | 15.2% | 16.9% | 29.8% |
| RYTM Dec | −734.9% | −175.9% | −87.5% | −61.5% |
| Peer median | −315.6% | −111.6% | −264.0% | −382.1% |
Return on equity, FY2022 to FY2025
Net income / shareholders' equity at the year end.
| Company | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| GRAL Dec | - | - | −81.0% | −15.8% |
| BEAM Dec | −39.4% | −13.5% | −51.4% | −6.5% |
| AGIO Dec | −21.1% | −43.4% | 43.7% | −34.6% |
| RVMD Dec | −36.3% | −23.9% | −26.5% | −69.3% |
| CYTK Dec | n/m | n/m | n/m | n/m |
| KYMR Dec | −31.6% | −37.2% | −26.8% | −19.7% |
| LGND Dec | −5.6% | 7.4% | −0.5% | 12.2% |
| RXRX Dec | −49.3% | −70.8% | −44.8% | −57.0% |
| LMAT Dec | 7.7% | 10.1% | 13.1% | 14.7% |
| RYTM Dec | −68.5% | −108.8% | n/m | −141.3% |
| Peer median | −33.9% | −30.6% | −26.5% | −27.2% |
Debt / equity, FY2022 to FY2025
Total debt / shareholders' equity at the year end.
EPS (diluted), FY2022 to FY2025
Diluted earnings per share, on today's share count after splits.
| Company | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| GRAL Dec | −$173.89 | −$47.21 | −$63.54 | −$11.11 |
| BEAM Dec | −$4.13 | −$1.72 | −$4.58 | −$0.81 |
| AGIO Dec | −$4.23 | −$6.33 | $11.64 | −$7.12 |
| RVMD Dec | −$3.08 | −$3.86 | −$3.58 | −$5.95 |
| CYTK Dec | −$4.33 | −$5.45 | −$5.26 | −$6.54 |
| KYMR Dec | −$2.87 | −$2.52 | −$2.98 | −$3.69 |
| LGND Dec | −$1.98 | $2.94 | −$0.22 | $6.13 |
| RXRX Dec | −$1.36 | −$1.58 | −$1.69 | −$1.44 |
| LMAT Dec | $0.93 | $1.34 | $1.93 | $2.52 |
| RYTM Dec | −$3.47 | −$3.20 | −$4.34 | −$3.11 |
| Peer median | −$3.08 | −$2.52 | −$2.98 | −$3.11 |
Fiscal years are lined up as each company's 10-K names them; the month next to a ticker is when its year ends. Hover a number for the XBRL line items and the filing; click it to open the filing on sec.gov. "n/m" means not meaningful: equity below zero, or a base so close to zero that the ratio says nothing. The peer median leaves out GRAL and needs at least three peers with the number. P/E, P/S and P/FCF at each year end appear here once the site has daily prices. What the same companies write about AI, tariffs and more
Sources
Each company's 10-K, from SEC's XBRL company facts. Every number links to its filing in the Inline XBRL viewer.
Also
Financials: GRAL's own statements, year by year. Compare: the whole peer group on one page.
Work with it
Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/GRAL/export.csv") into a cell.